

Committee Reports. Reports from Council committees on their work for 1996.

Open Forum—Emerging Issues: Internet and Home Banking. (Tentative) Committee reports concerning emerging issues and trends, focusing on the Internet and home banking.

Other matters previously considered by the Council or initiated by Council members also may be discussed.

Persons wishing to submit to the Council their views regarding any of the above topics may do so by sending written statements to Deanna Aday-Keller, Secretary, Consumer Advisory Council, Division of Consumer and Community Affairs, Board of Governors of the Federal Reserve System, Washington, D.C. 20551.

Information with regard to this meeting may be obtained from Ms. Aday-Keller, 202-452-6470. Telecommunications Device for the Deaf (TDD) users may contact Dorothea Thompson, 202-452-3544.

Board of Governors of the Federal Reserve System, September 26, 1996.

William W. Wiles

Secretary of the Board

[FR Doc. 96-25184 Filed 10-1-96; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Institute for Occupational Safety and Health

In accordance with section 10(a)(2) of the Federal Advisory Committee Act

(Pub. L. 92-463), the National Institute for Occupational Safety and Health, of the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH).

Time and Date: 10 a.m.-5 p.m., October 18, 1996.

Place: NIOSH Research Laboratory, 1095 Willowdale Road, Morgantown, West Virginia 26505.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

Purpose: The Board reviews research activities to provide guidance on the quality, timeliness, and efficacy of the Institute's programs.

Matters To Be Discussed: Agenda items include a report from the Director of NIOSH, the Musculoskeletal Program Evaluation, Extramural Activities, National Occupational Research Agenda, Health Hazard Evaluation Program Evaluation, EPA Science Advisory Board Communications, and future activities of the Board.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Bryan D. Hardin, Ph.D., Acting Executive Secretary, BSC, NIOSH, CDC, 1600 Clifton Road, NE, M/S D-35, Atlanta, Georgia 30333, telephone 404/639-3773.

Dated: September 26, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96-25169 Filed 10-1-96; 8:45 am]

BILLING CODE 4163-19-M

Food and Drug Administration

[Docket No. 96N-0340]

Lilly Research Laboratories, et al.; Withdrawal of Approval of 12 New Drug Applications, 8 Abbreviated Antibiotic Applications, and 23 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 12 new drug applications (NDA's), 8 abbreviated antibiotic applications (AADA's), and 23 abbreviated new drug applications (ANDA's). The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

EFFECTIVE DATE: October 2, 1996.

FOR FURTHER INFORMATION CONTACT: Olivia A. Vieira, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1046.

SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

Application no.	Drug	Applicant
NDA 6-470	Calcium Gluceptate	Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285.
NDA 8-826	Chlor-Trimeton Injection	Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033.
NDA 9-585	Cort-Dome (hydrocortisone, cream) Cream, 1/2%, 1%	Bayer Pharmaceutical, 400 Morgan Ln., West Haven, CT 06516-4175.
NDA 11-284	Meprospan (meprobamate) Capsules, 200 milligrams (mg) and 400 mg.	Wallace Laboratories, Half Acre Rd., P.O. Box 1001, Cranbury, NJ 08512-0181.
NDA 16-049	Innovar (fentanyl citrate/droperidol) for Injection	Janssen Pharmaceutica, 1125 Trenton-Harbourton Rd., P.O. Box 200 Titusville, NJ 08560-0200.
NDA 17-589	Solatene (betacarotene) Capsules	Hoffmann-LaRoche Inc., 340 Kingsland St., Nutley, NJ 07110-1199.
NDA 18-669	Niclocide (niclosamide) Tablets	Bayer Pharmaceutical.
NDA 18-806	Indomethacin Capsules, 25 mg and 50 mg	Warner Chilcott Laboratories, 200 Plymouth Rd., Ann Arbor, MI 28105.
NDA 18-830	Tambocor (flecainide acetate) 50, 100, 150 and 200 mg Tablets.	3M Pharmaceuticals, 3M Center, Bldg. 270-3A-01, St. Paul, MN 55144-1000.
NDA 19-329	Sodium Chloride Injection 23.4%	Fujisawa USA, Inc., Parkway North Center, Three Parkway North, Deerfield, IL 60015-2548.
NDA 50-550	Moxan (moxalactam disodium)	Lilly Research Laboratories.
NDA 50-565	Coatin (amdinocillin)	Hoffman-LaRoche, Inc.
AADA 60-107	Sterile Streptomycin Sulfate	Lilly Research Laboratories.